Skip to Main Content

Paper Details

The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment.
Haematologica
4
2021
-, EBF1, PDGFRB, T681I, dasatinib, imatinib
Dasatinib, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Protein Kinase Inhibitors, Receptor, Platelet-Derived Growth Factor beta, Trans-Activators
Author NameAffiliation
Thai Hoa TranCharles-Bruneau Cancer Center, University of Montreal, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Jonathan V NguyenBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Adrian SteculaDepartment of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Jon AkutagawaBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Anthony V MoormanWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University
Benjamin S BraunBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Andrej Sali (CM4AI)Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California san francisco
Charles G MullighanSt. Jude Children's Research Hospital
Neil P ShahDivision of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Yunfeng DaiCollege of Medicine and Public Health and Health Professions, University of Florida
Meenakshi DevidasSt. Jude Children's Research Hospital
Kathryn G RobertsSt. Jude Children's Research Hospital
Catherine C SmithDivision of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
Mignon L LohBenioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California san francisco
  • 1 - 15

Datasets